K Peony Yu Sells 2,851 Shares of FibroGen, Inc (FGEN) Stock

FibroGen, Inc (NASDAQ:FGEN) insider K Peony Yu sold 2,851 shares of the firm’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $51.00, for a total value of $145,401.00. Following the sale, the insider now directly owns 185,546 shares in the company, valued at approximately $9,462,846. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

K Peony Yu also recently made the following trade(s):

  • On Monday, August 21st, K Peony Yu sold 7,500 shares of FibroGen stock. The stock was sold at an average price of $41.03, for a total value of $307,725.00.
  • On Tuesday, August 8th, K Peony Yu sold 37,500 shares of FibroGen stock. The stock was sold at an average price of $50.58, for a total value of $1,896,750.00.
  • On Tuesday, August 1st, K Peony Yu sold 10,000 shares of FibroGen stock. The stock was sold at an average price of $33.48, for a total value of $334,800.00.
  • On Monday, July 10th, K Peony Yu sold 5,000 shares of FibroGen stock. The stock was sold at an average price of $32.98, for a total value of $164,900.00.

Shares of FibroGen, Inc (FGEN) opened at 52.40 on Friday. The firm has a 50 day moving average price of $43.31 and a 200 day moving average price of $32.07. FibroGen, Inc has a 1-year low of $15.60 and a 1-year high of $52.70. The firm’s market cap is $3.73 billion.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The business had revenue of $29.00 million during the quarter, compared to analyst estimates of $34.80 million. Analysts anticipate that FibroGen, Inc will post ($1.80) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.truebluetribune.com/2017/09/17/k-peony-yu-sells-2851-shares-of-fibrogen-inc-fgen-stock.html.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC raised its holdings in shares of FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 412 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its holdings in shares of FibroGen by 1.7% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 29,090 shares of the biopharmaceutical company’s stock worth $939,000 after acquiring an additional 474 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of FibroGen by 0.4% in the 1st quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after acquiring an additional 504 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of FibroGen by 15.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 696 shares during the last quarter. Finally, Tudor Investment Corp ET AL raised its holdings in shares of FibroGen by 7.1% in the 2nd quarter. Tudor Investment Corp ET AL now owns 12,095 shares of the biopharmaceutical company’s stock worth $391,000 after acquiring an additional 799 shares during the last quarter. Institutional investors own 47.49% of the company’s stock.

Several analysts recently commented on FGEN shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $75.00 price objective on shares of FibroGen in a research note on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) downgraded FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective on the stock. in a research note on Friday, July 21st. BidaskClub downgraded FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Stifel Nicolaus reissued a “buy” rating and issued a $80.00 price target on shares of FibroGen in a research note on Thursday. Finally, Citigroup Inc. reissued a “buy” rating and issued a $48.00 price target on shares of FibroGen in a research note on Monday, June 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $60.17.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply